Intraorgan biodistribution and dosimetry of 153Sm- ethylenediaminetetramethylene phosphonate in juvenile rabbit tibia: Implications for targeted radiotherapy of osteosarcoma

Journal of Nuclear Medicine

Volumn 46, Issue 12, 2005, Pages 2076-2082

  Essman, Stephanie C ^a,c   Lewis, Michael R ^a,b   Miller, William H ^a  

^a UNIVERSITY OF MISSOURI   (United States)

^b University of Missouri   (United States)

^c UNIVERSITY OF MISSOURI   (United States)

Author keywords

153Sm ethylenediaminetetramethylene phosphonate; Absorbed dose; Osteosarcoma; Physeal cartilage

Indexed keywords

ETHYLENEDIAMINETETRAMETHYLENE PHOSPHONATE SM 153; SAMARIUM 153; UNCLASSIFIED DRUG; ANALGESIC AGENT; ORGANOMETALLIC COMPOUND; ORGANOPHOSPHORUS COMPOUND; PHOSPHONIC ACID DERIVATIVE; RADIOISOTOPE; SAMARIUM ETHYLENEDIAMINETETRAMETHYLENEPHOSPHONATE;

ARTICLE; AUTORADIOGRAPHY; CONTROLLED STUDY; DRUG DISTRIBUTION; MALE; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; RABBIT; ANIMAL; BONE; BONE MARROW; CARTILAGE; CHEMISTRY; METABOLISM; METHODOLOGY; MONTE CARLO METHOD; PATHOLOGY; RADIATION DOSE; RADIATION EXPOSURE; RADIOMETRY; SCINTISCANNING; TIBIA; TIME; TISSUE DISTRIBUTION;

ANALGESICS, NON-NARCOTIC; ANIMALS; AUTORADIOGRAPHY; BONE AND BONES; BONE MARROW; CARTILAGE; MALE; MONTE CARLO METHOD; ORGANOMETALLIC COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; OSTEOSARCOMA; PHOSPHONIC ACIDS; RABBITS; RADIOISOTOPES; RADIOMETRY; RADIOTHERAPY DOSAGE; TIBIA; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 33644874921     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. 153Sm-EDTMP. J Pediatr Oncol Nurs. 1998;15:95-97.
2. 153Sm]EDTMP: a potential therapy for bone cancer pain. Semin Nucl Med. 1992;22:41-45.
3. Turner JH, Martindale AA, Sorby P, et al. Samarium-153 EDTMP therapy of disseminated skeletal metastasis. Eur J Nucl Med. 1989;15:784-795.
4. Serafini AN, Houston SJ, Resche I, et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebocontrolled clinical trial. J Clin Oncol 1998;16:1574-1581.
5. Bayouth JE, Macey DJ, Kasi LP, Fossella FV. Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases. J Nucl Med. 1994;35:63-69.
6. Lattimer JC, Corwin LA, Stapleton J, et al. Clinical and clinicopathologic response of canine bone tumor patients to treatment with samarium-153-EDTMP. J Nucl Med. 1990;31:1316-1325.
7. Franzius C, Bielack S, Vollet B, Jurgens H, Schober O. High-activity samarium-153-EDTMP therapy in unresectable osteosarcoma. Nuklearmedizin. 1999;38:337-340.
8. Franzius C, Bielack S, Flege S, Eckardt J, Sciuk J, Schober O. High-activity samarium-153-EDTMP therapy followed by autologous peripheral blood stem cell support in unresectable osteosarcoma. Nuklearmedizin. 2001;40:215-220.
9. 153Sm-EDTMP in recurrent canine osteosarcoma. J Small Anim Pract. 1996;37:241-246.
10. Anderson PM, Wiseman GA, Dispenzieri A, et al. High dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol. 2001;20:189-196.
11. Eifel PJ, Donaldson SS, Thomas PF. Response of growing bone to irradiation: a proposed late effects scoring system. Int J Radiat Oncol Biol Phys. 1995;31:1301-1307.
12. Melanotte PL, Follis RH. Early effects of x-irradiation on cartilage and bone. Am J Pathol. 1961;39:1-7.
13. Rutherford H, Dodd GD. Complications of radiation therapy: growing bone. Semin Roentgenol. 1974;7:15-26.
14. Probert JC, Parker BR. The effects of radiation therapy on bone growth. Radiology. 1975;114:155-162.
15. Parker RG, Berry HC. Late effects of therapeutic irradiation on the skeleton and bone marrow. Cancer. 1976;37:1162-1171.
16. Gonzalez DG, Breur K. Clinical data from irradiated growing long bones in children. Int J Radiat Oncol Biol Phys. 1983;9:841-846.
17. 153Sm-EDTMP on physeal and articular cartilage in juvenile rabbits. J Nucl Med. 2003;44:1510-1515.
18. Rivas R, Shapiro F. Structural states in the development of the long bones and epiphyses: a study in the New Zealand White rabbit. J Bone Joint Surg Am. 2002;84:85-100.
19. Heggie JCP. Radiation absorbed dose calculations for samarium-153-EDTMP localized in bone. J Nucl Med. 1991;32:840-844.
20. Briesmeister JE. MCNP: A general Monte Carlo N-Particle Transport Code, version 4C. Report LA-13709-M. Los Alamos, NM: Los Alamos National Laboratory; 2000.
21. ORNL. NUCDECAY: Nuclear Decay Data for Radiation Dosimetry Calculations for ICRP and MIRD. RSICC Data Library DLC-172. Oak Ridge, TN: Oak Ridge National Laboratory; 1995.
22. Goeckeler WF, Edwards B, Volkert WA, Holmes RA, Simon J, Wilson D. Skeletal localization of samarium-153 chelates: potential therapeutic bone agents. J Nucl Med. 1987;28:495-504.
23. 177Lu-DOTA-biotin pretargeted by CC49 scFv-streptavidin fusion protein in xenograft-bearing nude mice. Nucl Med Biol. 2004;31:213-223.
24. Frantz CH. Extreme retardation of epiphyseal growth from roentgen irradiation. Radiology. 1950;55:720-724.
25. Gonzalez DG, Van Dijk DP. Experimental studies on the response of growing bones to x ray and neutron irradiation. Int J Radiat Oncol Biol Phys. 1983;9:671-677.
26. Shapiro F. Epiphyseal and physeal cartilage vascularization: a light microscopic and tritiated thymidine autoradiographic study of cartilage canals in newborn and young postnatal rabbit bone. Anat Rec. 1998;252:140-148.
27. Shim SS, Leung G. Blood supply of the knee joint: a microangiographic study in children and adults. Clin Orthop. 1986;208:199-125.
28. Ballock RT, O'Keefe RJ. Physiology and pathophysiology of the growth plate. Birth Defects Res Part C Embryo Today. 2003;69:123-143.
29. Ghiron J, Volkert WA, Garlich J, Holmes RA. Determination of lesion to normal bone uptake ratios of skeletal radiopharmaceuticals by QARG. Nucl Med Biol. 1991;18:235-240.
30. Goldenberg DM. Advancing role of radiolabeled antibodies in the therapy of cancer. Cancer Immunol Immunother. 2003;52:281-296.
31. Subramanian G, McAfee JG, Thomas FD, Feld TA, Zapf-Longo C, Palladino E. New diphosphonate compounds for skeletal imaging: comparison with methylene diphosphonate. Radiology. 1983;149:823-828.
32. Dardzinski BJ, Laor T, Schmithorst VJ, Klosterman L, Graham TB. Mapping T2 relaxation time in the pediatric knee: feasibility with a clinical 1.5-T MR imaging system. Radiology. 2002;225:233-239.